Lv1
56 积分 2025-02-17 加入
Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy
1天前
求助中
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF
2天前
已完结
How Minimal Clinically Important Difference Works
8天前
已关闭
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy
11天前
已完结
Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure
27天前
已完结
Aficamten reduces cardiac contractility by modifying the actomyosin interaction
29天前
已完结
Heterogeneous Dysregulation of Myosin Super-Relaxation and Energetics in Hypertrophic Cardiomyopathy
29天前
已完结
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
29天前
已完结
Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure
29天前
已完结
Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy
29天前
已完结
皖公网安备34019202002308
